Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Charles Bennett and William Hrushesky.
Connection Strength

2.852
  1. Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on Adverse Reactions. Lancet Haematol. 2021 Aug; 8(8):e593-e604.
    View in: PubMed
    Score: 0.207
  2. The First 2?Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions. Oncologist. 2021 08; 26(8):e1418-e1426.
    View in: PubMed
    Score: 0.202
  3. Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997-2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR). EClinicalMedicine. 2021 Jan; 31:100693.
    View in: PubMed
    Score: 0.199
  4. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions. Lancet Oncol. 2020 12; 21(12):e575-e588.
    View in: PubMed
    Score: 0.198
  5. End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia. PLoS One. 2020; 15(6):e0234541.
    View in: PubMed
    Score: 0.192
  6. End of an era for erythropoiesis-stimulating agents in oncology. Int J Cancer. 2020 05 15; 146(10):2829-2835.
    View in: PubMed
    Score: 0.188
  7. Caveat Medicus: Clinician experiences in publishing reports of serious oncology-associated adverse drug reactions. PLoS One. 2019; 14(7):e0219521.
    View in: PubMed
    Score: 0.180
  8. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. Oncologist. 2019 04; 24(4):537-548.
    View in: PubMed
    Score: 0.175
  9. Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR). Cancer Med. 2017 Jul; 6(7):1541-1551.
    View in: PubMed
    Score: 0.156
  10. Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia. J Oncol Pract. 2017 06; 13(6):e562-e573.
    View in: PubMed
    Score: 0.155
  11. Interpretation of surrogate endpoints in the era of the 21st Century Cures Act. BMJ. 2016 Dec 30; 355:i6286.
    View in: PubMed
    Score: 0.151
  12. Generic oncology drugs: are they all safe? Lancet Oncol. 2016 Nov; 17(11):e493-e501.
    View in: PubMed
    Score: 0.149
  13. Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia. Br J Haematol. 2018 01; 180(2):301-304.
    View in: PubMed
    Score: 0.148
  14. Editorial Comment. Urology. 2016 07; 93:74-5.
    View in: PubMed
    Score: 0.144
  15. Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells. JAMA Oncol. 2016 Jan; 2(1):134-6.
    View in: PubMed
    Score: 0.141
  16. Adding Bevacizumab to the Treatment of Patients With Non-Small-Cell Lung Cancer: Caveat Emptor. J Oncol Pract. 2015 Sep; 11(5):363-4.
    View in: PubMed
    Score: 0.137
  17. Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncol. 2014 Dec; 15(13):e594-e605.
    View in: PubMed
    Score: 0.130
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.